0001262463-22-000120.txt : 20220912 0001262463-22-000120.hdr.sgml : 20220912 20220912132852 ACCESSION NUMBER: 0001262463-22-000120 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220906 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220912 DATE AS OF CHANGE: 20220912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthtech Solutions, Inc./UT CENTRAL INDEX KEY: 0001307624 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 842528660 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51012 FILM NUMBER: 221238223 BUSINESS ADDRESS: STREET 1: 181 DANTE AVENUE CITY: TUCKAHOE STATE: NY ZIP: 10707 BUSINESS PHONE: 844-926-3399 MAIL ADDRESS: STREET 1: 181 DANTE AVENUE CITY: TUCKAHOE STATE: NY ZIP: 10707 FORMER COMPANY: FORMER CONFORMED NAME: HYB Holding Corp. DATE OF NAME CHANGE: 20200319 FORMER COMPANY: FORMER CONFORMED NAME: XINYINHAI TECHNOLOGY, LTD. DATE OF NAME CHANGE: 20061016 FORMER COMPANY: FORMER CONFORMED NAME: IRON STAR DEVELOPMENT, INC. DATE OF NAME CHANGE: 20041102 8-K 1 hltt8k.htm FORM 8-K
0001307624 false 0001307624 2022-09-06 2022-09-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

 

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 6, 2022

______________

 

HEALTHTECH SOLUTIONS, INC./UT

(Exact name of registrant as specified in its charter)

______________

 

Utah 0-51012 84-2528660
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

181 Dante Avenue, Tuckahoe, New York 10707

(Address of Principal Executive Office) (Zip Code)

 

844-926-3399

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

 1 
 

ITEM 3.02UNREGISTERED SALE OF EQUITY SECURITIES

 

On September 6, 2022 the Registrant’s Board of Directors approved a grant of options to purchase up to 15,000,000 shares of the Registrant’s common stock. The options were issued in compensation for the non-interest-bearing loans made by several of the Registrant’s shareholders to the Registrant during the past twelve months, which exceeded $1,500,000 and which remain outstanding. By agreement among the lenders, the options were issued to Storm Funding, LLC.

The options may be exercised during the next three years to purchase shares of the common stock for $0.25 per share, although the holder may not at any time exercise the options to purchase a number of shares that, when combined with all shares owned by the holder and its affiliates, would exceed 4.99% of the Registrant’s outstanding shares. Payment for the shares may be made in cash of by cashless exercise.

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibits

 

10-a

Common Stock Purchase Warrant dated September 6, 2022 issued to Storm Funding, LLC.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Healthtech Solutions, Inc.
     

Date: September 12, 2022


 By:  

/s/ Manuel E. Iglesias

Manuel E. Iglesias, President

  

 2 

 

 EX-10 2 ex10a.htm EXHIBIT 10-A

COMMON STOCK PURCHASE OPTION

HEALTHTECH SOLUTIONS, INC.

 

Option Holder: Storm Funding, LLC Grant Date: September 6, 2022
Option Shares: 15,000,000 Termination Date: September 5, 2025

Exercise Price: $0.25 (subject to adjustment)

 

  

THIS COMMON STOCK PURCHASE OPTION (the “Option”) certifies that, for value received, the Option Holder specified above or assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Grant Date specified above and on or prior to the close of business on the Termination Date specified above (said period being the "Exercise Period"), to subscribe for and purchase from Healthtech Solutions, Inc., a Utah corporation (the “Company”), up to the number of Option Shares specified above.

Section 1. Exercise.

a)              Exercise of Option. Exercise of the purchase rights represented by this Option may be made, in whole or in part, at any time or times during the Exercise Period by delivery to the Company at its executive offices of a duly executed copy of the Notice of Exercise Form annexed hereto; and, if the Holder opts to make cash payment, within 3 business days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check or otherwise by agreement with the Company. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Option to the Company until the Holder has purchased all of the Option Shares available hereunder and the Option has been exercised in full, in which case, the Holder shall surrender this Option to the Company for cancellation within 3 business days of the date the final Notice of Exercise is delivered to the Company.

b)             Exercise Price. The exercise price per share of the Common Stock under this Option shall be the Exercise Price specified above, subject to adjustment hereunder (the “Exercise Price”).

c)              Cashless Exercise. If there is a Market Value (as defined below) for the Common Stock, then in lieu of cash payment, the Option may be exercised at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a certificate for the number of Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = the Market Value on the day immediately preceding delivery of the Notice of Exercise;
(B) = Exercise Price of this Option; and
(X) = the number of Option Shares issuable upon exercise of this Option in accordance with the terms of this Option by means of a cash exercise rather than a cashless exercise.

 1 
 

The "Market Value" for this purpose shall be, in the order of priority:

i.If there is quoted on any securities market a bid price for the common stock, the Market Value will be the average of the closing bid prices for the five trading days preceding the delivery of the Notice of Exercise.
ii.If there is no bid price quoted, the Market Value shall be the cash-equivalent price per share in the most recent arms-length sale of stock for cash or assets by the Company, provided (A) such sale closed no more than 12 months prior to the delivery of the Notice of Exercise or (B) such sale is contemplated by a contract binding upon the Company at the time of delivery of the Notice of Exercise.
iii.If neither of the aforesaid criteria determines a Market Value, then the Exercise Price must be paid in cash.

d)             Holder’s Exercise Limitations. The Company shall not effect any exercise of this Option, and a Holder shall not have the right to exercise any portion of this Option, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Option. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Option beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.  Except as set forth in the preceding sentence, for purposes of this Section 2(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(d) applies, the determination of whether this Option is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Option is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Option is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Option is exercisable, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this

 2 
 

Section 2(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Option, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor Holder of this Option. The provisions of this Section may be waived by a Holder (but only as to itself and not to any other Holder) upon not less than 63 days prior notice to the Company. Other Holders shall be unaffected by any such waiver.

e)              Mechanics of Exercise.

i.                  Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Issuer to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within 5 business days from the delivery to the Company of the Notice of Exercise Form, surrender of this Option (if required) and payment of the aggregate Exercise Price as set forth above. This Option shall be deemed to have been exercised on the date the Exercise Price or notice of cashless exercise is received by the Company. The Option Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Option has been exercised by payment to the Company of the Exercise Price (or by cashless exercise).

ii.                  No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Option. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price.

iii.                  Charges, Taxes and Expenses. Issuance of certificates for Option Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder.

 

 3 
 

Section 2. Certain Adjustments.

a)              Stock Dividends and Splits. If the Company, at any time while this Option is outstanding: (i) pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Option shall be proportionately adjusted such that the aggregate Exercise Price of this Option shall remain unchanged.

b)             Fundamental Transaction. If, at any time while this Option is outstanding, (i) the Company effects any merger or consolidation of the Company with or into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Option, the Holder shall have the right to receive, for each Option Share that would have been issuable in the absence of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such merger, consolidation or disposition of assets by a holder of a share of Common Stock immediately prior to such event. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new option consistent with the foregoing provisions.

c)              Notice to Holder.

i.                  Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

 4 
 

ii.                  Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or options to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be emailed to the Holder at its last email address as it shall appear upon the records of the Company, at least five calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or options, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or options are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to email such notice or any defect therein or in the emailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

Section 3. Miscellaneous.

a)              No Rights as Stockholder Until Exercise. This Option does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise hereof.

b)             Restrictions. The Holder acknowledges that the Option Shares acquired upon the exercise of this Option, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

c)              Person Defined. As used herein, the term "Person" means a natural person, a partnership, a corporation, an association, a joint stock company, a limited liability company, a trust, a joint venture, an unincorporated organization or a governmental entity.

IN WITNESS WHEREOF, the Company has caused this Option to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

HEALTHTECH SOLUTIONS, INC.

 

 

 

By:_________________________________

Name: Manuel E. Iglesias

Title: President

 

 

 

 5 
 

NOTICE OF EXERCISE

 

To: HEALTHTECH SOLUTIONS, INC.

 

(1)  The undersigned hereby elects to purchase ____________ Option Shares of the Company pursuant to the terms of the attached Option, and tenders herewith payment of the exercise price in full.

(2)  Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] the cancellation of such number of Option Shares as is necessary, in accordance with the formula set forth in subsection 1(c), to exercise this Option with respect to the number of Option Shares recited above pursuant to the cashless exercise procedure set forth in subsection 1(c).

Market Value Per Share: ________________________

Holder determines the Market Value on the basis of the following evidence:

_________________________________________________________________

_________________________________________________________________

_________________________________________________________________

(3)  Please issue a certificate or certificates representing said Option Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

 

 

The Option Shares shall be delivered by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

 

SIGNATURE OF HOLDER: ___________________________________________________________

 

Name of Holder: _____________________________________________________________________

 

Date: ______________________________________________________________________________

 

 

   
 

 

 

 EX-101.SCH 3 hltt-20220906.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hltt-20220906_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hltt-20220906_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 06, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 06, 2022
Entity File Number 0-51012
Entity Registrant Name HEALTHTECH SOLUTIONS, INC./UT
Entity Central Index Key 0001307624
Entity Tax Identification Number 84-2528660
Entity Incorporation, State or Country Code UT
Entity Address, Address Line One 181 Dante Avenue
Entity Address, City or Town Tuckahoe
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10707
City Area Code 844
Local Phone Number 926-3399
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 7 hltt8k_htm.xml IDEA: XBRL DOCUMENT 0001307624 2022-09-06 2022-09-06 iso4217:USD shares iso4217:USD shares 0001307624 false 8-K 2022-09-06 HEALTHTECH SOLUTIONS, INC./UT UT 0-51012 84-2528660 181 Dante Avenue Tuckahoe NY 10707 844 926-3399 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 19 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://healthtech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hltt8k.htm ex10a.htm hltt-20220906.xsd hltt-20220906_lab.xml hltt-20220906_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hltt8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "hltt8k.htm" ] }, "labelLink": { "local": [ "hltt-20220906_lab.xml" ] }, "presentationLink": { "local": [ "hltt-20220906_pre.xml" ] }, "schema": { "local": [ "hltt-20220906.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 19, "memberCustom": 0, "memberStandard": 0, "nsprefix": "HLTT", "nsuri": "http://healthtech.com/20220906", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hltt8k.htm", "contextRef": "From2022-09-06to2022-09-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://healthtech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hltt8k.htm", "contextRef": "From2022-09-06to2022-09-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001262463-22-000120-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001262463-22-000120-xbrl.zip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end